Verrica out of Nasdaq compliance after director resignation; cure period granted

Verrica Pharmaceuticals Inc.

Craig Ballaron resigned from Board effective October 2, 2024.
Board appointed Diem Nguyen to Audit Committee on October 7, 2024.
Resignation caused loss of majority independent directors, violating Nasdaq Rule 5605(b)(1).
Nasdaq provided cure period until next annual meeting or October 2, 2025.
Company expects to regain compliance within the cure period.

item 5.02 item 3.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Craig Ballaron

member of the Board of Directors

VRCA · Verrica Pharmaceuticals Inc.

Effective: 2024-10-02
Filed: October 8, 2024, 7:59 PM ET

On October 2, 2024, Craig Ballaron, a member of the Board of Directors (the “Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”), notified the Company that he was resigning from the Board and all committees of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Craig Ballaron resigned as member of the Board of Directors at Verrica Pharmaceuticals Inc..

Action: resigned
Role: member of the Board of Directors

Exact text from the filing

On October 2, 2024, Craig Ballaron, a member of the Board of Directors (the “Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”), notified the Company that he was resigning from the Board and all committees of the Board, effective immediately.

View on SEC.gov

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-234391

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.